GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » Intrinsic Value: Projected FCF

Bio View (XTAE:BIOV) Intrinsic Value: Projected FCF : ₪0.22 (As of May. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Bio View Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-27), Bio View's Intrinsic Value: Projected FCF is ₪0.22. The stock price of Bio View is ₪0.287. Therefore, Bio View's Price-to-Intrinsic-Value-Projected-FCF of today is 1.3.

The historical rank and industry rank for Bio View's Intrinsic Value: Projected FCF or its related term are showing as below:

XTAE:BIOV' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.11   Med: 0.18   Max: 1.74
Current: 1.3

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Bio View was 1.74. The lowest was 0.11. And the median was 0.18.

XTAE:BIOV's Price-to-Projected-FCF is ranked better than
61.41% of 355 companies
in the Medical Devices & Instruments industry
Industry Median: 1.73 vs XTAE:BIOV: 1.30

Bio View Intrinsic Value: Projected FCF Historical Data

The historical data trend for Bio View's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View Intrinsic Value: Projected FCF Chart

Bio View Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.62 0.23 0.32 0.29 0.22

Bio View Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.24 0.29 0.28 0.22

Competitive Comparison of Bio View's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Bio View's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio View's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Bio View's Price-to-Projected-FCF falls into.



Bio View Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Bio View's Free Cash Flow(6 year avg) = ₪0.92.

Bio View's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*0.92432+27.305*0.8)/139.078
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio View  (XTAE:BIOV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Bio View's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.287/0.22033572087018
=1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio View Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Bio View's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio View (XTAE:BIOV) Business Description

Traded in Other Exchanges
N/A
Address
3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View (XTAE:BIOV) Headlines

No Headlines